Sequential Skin Ltd Secures £6.1m Seed Round to Advance Microbiome Testing Platform

London-based biotech startup Sequential Skin Ltd has closed a £6.1m seed funding round, achieving a post-money valuation of £23.6m. The allotment was finalised on March 18, 2026, with the official filing recorded today.

Incorporated in April 2020 and led by founders Oliver Worsley and Albert Dashi, Sequential Skin operates at the intersection of genomics and dermatology. The company provides at-home genetic and microbiome testing kits that analyse skin health, allowing individual consumers to receive highly personalised skincare recommendations and products. Beyond its direct-to-consumer offering, the four-employee firm provides clinical microbiome research, testing, and product validation services to B2B clients across the skincare, haircare, and healthcare industries.

The skincare market is historically saturated with generic products that often fail to address individual biological differences. Sequential Skin solves this problem by using deep molecular analysis and next-generation sequencing to understand how an individual's genetics, epigenetics, and local environment affect their skin microbiome. This data-driven approach helps consumers manage inflammatory conditions like atopic dermatitis, rosacea, and acne. For B2B clients, the testing platform enables brands to systematically design and validate breakthrough ingredient combinations using non-invasive human clinical samples, offering a scientifically rigorous alternative to traditional animal testing.

The £6.1m seed round brings the company to a post-money valuation of £23.6m. Recent backers of the company include Sparkfood and Corundum Systems Biology, alongside Dermazone Holdings, SOSV, and Scrum Ventures. This represents a significant step up from the company's earlier funding efforts, which included a £1.2m seed tranche in late 2021 led by Metaplanet. The new capital will be used to further develop its artificial intelligence-powered discovery platform, which already leverages a clinical dataset of over 50,000 skin samples to identify novel biomarkers.

Sequential Skin's latest raise highlights the growing investor appetite for personalised health tech and biotech solutions in the UK. The global skin microbiome market is expanding rapidly, driven by consumer demand for scientifically backed formulations, and is projected to reach over £2.2 billion by 2032. Furthermore, as regulatory shifts increasingly favour alternative testing methods over traditional animal models, the UK alternative technology sector is forecast to be worth £2.5 billion by 2026. Sequential Skin is well positioned to capitalise on these trends, bridging the gap between clinical-grade genomic research and consumer skincare while maintaining a lean operational footprint.